Drugs / SM-020
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT06409195 | Mar → Nov 2024 | skin carcinoma | DermBiont, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT06099080 | Nov 2023 → Jul 2024 | dermatosis papulosa nigra | DermBiont, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05136144 | Oct 2021 → May 2024 | seborrheic keratosis | DermBiont, Inc. | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06108024 Comparator | Nov 2023 → Sep 2024 | seborrheic keratosis | DermBiont, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SM-020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06099080 ↗ |
| Action | Inhibit | “Topical Akt Inhibitor SM-020 Gel” NCT05136144 ↗ |
| Route | Topical | “Topical Akt Inhibitor SM-020 Gel” NCT05136144 ↗ |